Add to Cart View Cart/Checkout More Products

Volume 12, 2008 CD

Six back issues of The International Journal of Pharmaceutical Compounding from 2008 on one convenient CD.
Only $95 per CD.
(Multiple Theme or Library CD orders priced at: 2 to 5 = $85; 6 to 9 = $75; 10 or more = $65 each.)

  • Permanant storage and easy retrieval of IJPC articles, formulations, SOP's and more.
  • Print IJPC articles in color for your marketing needs.

The back issues are stored as a high-resolution, full-color Adobe Portable Document Format (.pdf) file, complete with an electronic Table of Contents.

They may be searched by keyword and printed by the page. Software to read the PDF file is freely available from the Adobe Reader page.

Issues
Volume/IssueDateTitle
Vol. 12 No. 1 January/February 2008 Compounding for Hospice and Cancer Patients
Vol. 12 No. 2 March/April 2008 Compounding Around the World
Vol. 12 No. 3 May/June 2008 Pain Management
Vol. 12 No. 4 July/August 2008 Hormone Replacement Therapy
Vol. 12 No. 5 September/October 2008 Veterinary Compounding
Vol. 12 No. 6 November/December 2008 Arthritis and Immunological Diseases

Articles
Volume/IssuePageTitle
Vol. 12 No. 1 4 PreScription: Year Number 12…And Still Much Work to Do
Vol. 12 No. 1 8 Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
Vol. 12 No. 1 16 Cancer-Related Terminology: Glossaries for Compounding Pharmacists and Their Clients
Vol. 12 No. 1 28 Hospice and Compounding Pharmacy: Once Inseperable
Vol. 12 No. 1 38 Disposing of Expired Drugs and Chemicals: New Options for Compounders
Vol. 12 No. 1 48 Websites: Keeping Current in 2008
Vol. 12 No. 1 50 Quality-Control Analytical Methods: Stability Versus Potency Testing: The Madness is in the Method
Vol. 12 No. 1 54 Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 5: Verification of Accuracy, Sterility, and Sterilization of Compounded Preparations
Vol. 12 No. 1 62 Calculations: Compounding for Cancer Patients
Vol. 12 No. 1 63 Standard Operating Procedure: Compliance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996
Vol. 12 No. 1 64 Cyclosporine Topical Gel
Vol. 12 No. 1 65 Diclofenac Sodium 1% Soft-Patch Gel
Vol. 12 No. 1 66 Diclofenac Sodium 1% Soft-Patch Lipophilic Gel
Vol. 12 No. 1 67 Diltiazem 5% in Lipoderm, Veterinary
Vol. 12 No. 1 68 Emetine Hydrochloride 30-mg/mL Injection
Vol. 12 No. 1 69 Flosulide 10-mg/mL Injection
Vol. 12 No. 1 70 Pentoxifylline 20-mg/mL Oral Suspension
Vol. 12 No. 1 71 Piroxicam 1% Soft-Patch Lipophilic Gel
Vol. 12 No. 1 72 Piroxicam 1% Soft-Patch Topical Gel
Vol. 12 No. 1 73 Trimethoprim 10-mg/mL Oral Suspension
Vol. 12 No. 1 74 Specialty Compounding for Improved Patient Care: 2006 National Survey of Compounding Pharmacists
Vol. 12 No. 1 83 Room Temperature Stability of Injectable Succinylcholine Dichloride
Vol. 12 No. 1 86 2007 Reviewers
Vol. 12 No. 1 87 PostScription: Consumer Options for Disposal of Unused Medications
Vol. 12 No. 2 92 PreScription: Compounding Around the World
Vol. 12 No. 2 94 Current Compounding Practices in Europe
Vol. 12 No. 2 102 Compounding Around the World
Vol. 12 No. 2 116 Establishing a Quality-Assurance Program for Hospital Compounding
Vol. 12 No. 2 122 Hormone Therapy: It's Time for a Second Opinion
Vol. 12 No. 2 128 Newsletters: An Essential Marketing Tool
Vol. 12 No. 2 130 Quality-Control Analytical Methods: Minimizing the Probability of Out-of-Specification Preparations: Results that Make You Say…Hmmm!
Vol. 12 No. 2 136 Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 6: 2008 Revisions to Chapter <797>
Vol. 12 No. 2 145 Calculations
Vol. 12 No. 2 146 Acyclovir 5% Topical Ointment
Vol. 12 No. 2 147 Alum 6.5% Topical Cream
Vol. 12 No. 2 148 Aminacrine Hydrochloride 0.1% Cream
Vol. 12 No. 2 149 Butesin Picrate 1% ointment
Vol. 12 No. 2 150 Carbamazepine Topical Preparations
Vol. 12 No. 2 151 Chlorhexidine Gel
Vol. 12 No. 2 152 EDTA 1% Cream
Vol. 12 No. 2 153 Erythromycin 1% and Neomycin Sulfate Ointment
Vol. 12 No. 2 154 Heparin Gel-Cream
Vol. 12 No. 2 155 Hydrogen Peroxide 8% Cream
Vol. 12 No. 2 156 Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Vol. 12 No. 2 161 Chemical Stability of Tramadol Hydrochloride Injection
Vol. 12 No. 2 163 Pharmaceutical Development of Enteric-Release Hard Gelatin Capsules in the Compounding Setting
Vol. 12 No. 2 170 Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Vol. 12 No. 2 174 PostScription: Accreditation by the Pharmacy Compounding Accreditation Board: Raising the Bar for Patient Care
Vol. 12 No. 3 180 PreScription: Pain!
Vol. 12 No. 3 182 Topical Treatment of Neuropathic Pain
Vol. 12 No. 3 192 Compounded Local Anesthetics to Minimize Pain from Medical Procedures
Vol. 12 No. 3 200 Dilution and Compounding of Ziconotide for Intrathecal Administration
Vol. 12 No. 3 208 Pharmacy Compounding at the University of Connecticut: Secundum Artem et Scientia
Vol. 12 No. 3 213 Developing and Implementing a Clinical Pharmacy Rotation in a Community Compounding Pharmacy
Vol. 12 No. 3 216 Microbial Air-Sampling Equipment, Part 1: Meeting United States Pharmacopeia Chapter <797> Standards
Vol. 12 No. 3 230 Communication with Pharmacy Technicians: How to Reduce Stress and Improve Pharmacy Operations
Vol. 12 No. 3 234 Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 3: Developing a Program of Quality Assurance and Continuous Quality Improvement
Vol. 12 No. 3 238 Litigating the Legality of Compounding: The Medical Center Pharmacy Case
Vol. 12 No. 3 242 Developing a Niche Marketing Strategy
Vol. 12 No. 3 244 Web 2.0 and Health 2.0: Are You In?
Vol. 12 No. 3 247 A Process Verification Model for Quality Assurance in a Compounding Pharmacy
Vol. 12 No. 3 252 Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 7: Microbial Contamination Risk Levels, 12-Hour Use, and Immediate Use
Vol. 12 No. 3 258 Calculations
Vol. 12 No. 3 259 Standard Operating Procedure: Dealing with Patients Experiencing Pain: Presenting without a Prescription
Vol. 12 No. 3 260 African Scalp Lotion
Vol. 12 No. 3 261 Benzyl Benzoate Lotion
Vol. 12 No. 3 262 Calcium Gluconate 2.5% Topical Gel
Vol. 12 No. 3 263 Lubricating Gel
Vol. 12 No. 3 264 Meloxicam 0.3% Topical Gel
Vol. 12 No. 3 265 Miconazole Nitrate 2%, Deoxy-D-Glucose 0.2%, and Hydrocortisone 0.4% Lip Balm
Vol. 12 No. 3 266 Potassium Nitrate/Benzocaine/Tetracaine Dental Gel
Vol. 12 No. 3 267 Promethazine Hydrochloride 2.5-mg/mL Rectal Solution
Vol. 12 No. 3 268 Tolnaftate 1% Antifungal Microemulsion
Vol. 12 No. 3 269 Valsartan 4-mg/mL Oral Liquid
Vol. 12 No. 3 270 Evaluation of the Percutaneous Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo Skin Model
Vol. 12 No. 3 274 Chemical Stability of Naltrexone Hydrochloride Injection
Vol. 12 No. 3 276 Compatibility of Caspofungin Acetate Injection with Other Drugs During Simulated Y-Site Coadministration
Vol. 12 No. 3 279 PostScription: A Contemporary Perspective on Compounding Education
Vol. 12 No. 4 284 PreScription: First Estriol, Then What?
Vol. 12 No. 4 286 Estriol: Women's Choice vs. A Manufacturer's Greed
Vol. 12 No. 4 295 Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women
Vol. 12 No. 4 306 The Magic of Magnesium
Vol. 12 No. 4 310 Progesterone and Traumatic Brain Injury: A Review of Literature
Vol. 12 No. 4 316 Beyond-Use Dating, Labeling, Delivery, and Storage of Compounded and Repackaged Mediations in a Hospital or Institutional Setting
Vol. 12 No. 4 321 Microbial Air-Sampling Equipment, Part 2: Experiences of Compounding Pharmacists
Vol. 12 No. 4 329 Recommendations for Overcoming Barriers to Medication Therapy Management Implementation, Part 1: Review of Literature
Vol. 12 No. 4 334 Using Readily Available Technology to Start or Enhance Pharmacy-Based Immunization
Vol. 12 No. 4 338 Marketing for Your Community
Vol. 12 No. 4 340 Quality-Control Analytical Methods: Homogeneity of Dosing Forms
Vol. 12 No. 4 344 Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 8; Stability and Beyond-Use Dating
Vol. 12 No. 4 354 Calculations
Vol. 12 No. 4 355 Chloroxylenol 1% and Chlorhexidine Diacetate 1% Topical Powder
Vol. 12 No. 4 356 Silicone Cream
Vol. 12 No. 4 357 Sodium Chloride 0.9% Ointment
Vol. 12 No. 4 358 Squalene 0.2% Cream
Vol. 12 No. 4 359 Sucralfate and Hyaluronic Acid Ointment
Vol. 12 No. 4 360 Tretinoin and (-)Alpha-Bisabolol Gel
Vol. 12 No. 4 361 Tretinoin and Dexpanthenol Gel
Vol. 12 No. 4 362 Ultrasonic Adhesive Gel
Vol. 12 No. 4 363 Vitamin A Suppository
Vol. 12 No. 4 364 Zirconium Oxide Lotion
Vol. 12 No. 4 365 Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada
Vol. 12 No. 4 368 Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration
Vol. 12 No. 4 372 Chemical Stability of Perphenazine in Two Commercially Available Vehicles for Oral Liquid Dosage Forms
Vol. 12 No. 4 375 PostScription: It Is Not Just What You Say…But How You Say It!
Vol. 12 No. 5 382 PreScription: Compounding Around the World
Vol. 12 No. 5 384 Canine Public Servants: Caring for Drug Detection Dogs
Vol. 12 No. 5 392 Transdermal Amlodipine Besylate in Lipoderm for the Treatment of Feline Hypertension: A Report of Two Cases
Vol. 12 No. 5 398 Veterinary Compounding for Myasthenia Gravis
Vol. 12 No. 5 402 Equine Anesthesia: Triple Drip
Vol. 12 No. 5 405 Publication Expansion of United States Pharmacopeial Convention's Veterinary Standards and Clinical Information
Vol. 12 No. 5 410 Golden Ticket to the United States Pharmacopeial Convention's Veterinary Internship
Vol. 12 No. 5 414 Medication Therapy Management Implementation, Part 2: Study Methodologies, Barriers, and Recommendations to Overcome Barriers
Vol. 12 No. 5 420 Insurance for the Compounding Pharmacy Business, Part 1: Who Is Covered?
Vol. 12 No. 5 426 Excipient Choices for Special Populations
Vol. 12 No. 5 432 Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 4L Tips for "Last Minute" Preparations
Vol. 12 No. 5 434 Technology for the Patient-Centric Pharmacy
Vol. 12 No. 5 438 Marketing: Taking Your Show on the Road
Vol. 12 No. 5 440 Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 9: Immediate-Use Compounded Sterile Preparations
Vol. 12 No. 5 444 Calculations
Vol. 12 No. 5 446 Aceclofenac 1.5% Gel-Cream
Vol. 12 No. 5 447 Acetaminophen 10-mg/mL Rectal Solution
Vol. 12 No. 5 448 Carnitine 400-mg/mL and Coenzyme Q10 10-mg/mL Solution
Vol. 12 No. 5 449 Dichlorobenzyl Alcohol Tooth Gel
Vol. 12 No. 5 450 Estradiol 0.1% Vaginal Solution
Vol. 12 No. 5 451 Flurandrenolide Topical Film
Vol. 12 No. 5 452 Ketoprofen 20% Topical Solution
Vol. 12 No. 5 453 Lidocaine Adhesive System Gel
Vol. 12 No. 5 454 Piroxicam 5% and Dexpanthenol 5% Gel
Vol. 12 No. 5 455 Propafenone 1.5-mg/mL Oral Liquid
Vol. 12 No. 5 456 Testing the Long-Term Stability of Vancomycin Ophthalmic Solution
Vol. 12 No. 5 460 Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration
Vol. 12 No. 5 463 Chemical Stability of Admixtures Combining Ziconotide with Fentanyl or Sufentanil During Simulated Intrathecal Administration
Vol. 12 No. 5 467 PostScription: The International Society of Pharmaceutical Compounding: A Discussion of Its Importance from the Perspective of ISPhC Leadership
Vol. 12 No. 6 474 Prescription: Is "Globalization" a Good Idea?
Vol. 12 No. 6 476 Arthritis Epidemiology Impacts Pharmacists
Vol. 12 No. 6 482 Compounding Challenges for Immunocompromised Patients
Vol. 12 No. 6 488 Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism
Vol. 12 No. 6 498 Case Reports: Compounding to Relieve Arthritis Pain
Vol. 12 No. 6 505 Symbols: Historic and Current Uses
Vol. 12 No. 6 508 Medication Therapy Management Implementation, Part 3: Barriers and Recommendations to Overcome Barriers
Vol. 12 No. 6 514 Insurance for the Compounding Pharmacy Business, Part 2: What, When, and Where
Vol. 12 No. 6 524 Quality-Control Analytical Methods: Overview of Beyond-Use Dating for Compounded Sterile Preparations
Vol. 12 No. 6 530 Basics of Compounding: United States Pharmacopeia General Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 10: First Revision: The Main Changes, Events, and Rationale
Vol. 12 No. 6 537 Branding: Give Your Small Business a Big Image
Vol. 12 No. 6 539 Calculations
Vol. 12 No. 6 540 Cyclobenzaprine Hydrochloride 0.5% and Diclofenac Sodium 3% in Pluronic Lecithin Organogel
Vol. 12 No. 6 541 Cyclobenzaprine Hydrochloride 1%, Dextromethorphan Hydrobromide 10%, Guaifenesin 10%, and Indomethacin 20% Penetrating Gel
Vol. 12 No. 6 542 Glycerin, Sterile
Vol. 12 No. 6 543 Indomethacin 2% in Pluronic Lecithin Organogel
Vol. 12 No. 6 544 Ketorolac Tromethamine 2% Topical Gel
Vol. 12 No. 6 545 Liothyronine Sodium (T3) 5-mcg/Hydrocortisone 5-mg Slow-Release Capsules
Vol. 12 No. 6 546 Liothyronine Sodium (T3) 5-mcg/0.1-mL Transdermal Cream
Vol. 12 No. 6 547 Liothyronine Sodium (T3) 5-mcg/Selenium 100-mcg Slow-Release Capsules
Vol. 12 No. 6 548 Liothyronine Sodium (T3) 5-mcg Slow-Release Capsules
Vol. 12 No. 6 549 Morphine Sulfate 20-mg and Prochlorperazine Maleate 10-mg Troches
Vol. 12 No. 6 550 Physical Compatibility and Chemical Stability of a Concentrated Solution of Atropine Sulfate (2 mg/mL) for Use as an Antidote in Nerve Agent Casualties
Vol. 12 No. 6 553 Chemical Stability of Admixtures Containing Ziconotide 25 mcg/mL and Morphine Sulfate 10 mg/mL or 20 mg/mL During Simulated Intrathecal Administration
Vol. 12 No. 6 558 Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System
Vol. 12 No. 6 565 PostScription: Supporting Compounding Around the World